Approved indications: Intravenous tacrolimus is indicated, in combination with other immunosuppressants, to prevent organ rejection after allogeneic kidney, liver, heart, or lung transplantation in adult and pediatric patients who cannot take oral tacrolimus and need temporary IV therapy.

Off-label uses: Systemic tacrolimus (usually oral, occasionally IV in hospital) may be used off-label for conditions such as graft-versus-host disease after stem cell transplant, myasthenia gravis, Crohn disease and other autoimmune or severe inflammatory disorders; evidence ranges from case series and observational studies to small trials, so decisions are individualized and specialist-driven.

Efficacy expectations:

• When started around the time of transplant and combined with other agents (for example, mycophenolate and corticosteroids), tacrolimus significantly reduces the rate of acute rejection episodes compared with older regimens such as cyclosporine in many studies.
• The protective effect begins as soon as adequate blood levels are reached, typically within the first days after transplant; most benefit is seen in the high-risk early period (first weeks to months).
• Long-term, tacrolimus-based regimens provide graft and patient survival that are at least comparable and often superior to cyclosporine, though risks of diabetes and neurotoxicity can be higher, so regimens are tailored to balance rejection risk and toxicity.

Response monitoring: Clinicians track organ function tests (for example, creatinine for kidney, liver enzymes for liver, echocardiography for heart, lung function tests for lung) and tacrolimus blood levels to adjust dosing and confirm that the drug is effectively preventing rejection without causing excessive toxicity.

Typical IV dosing:

• Adults with kidney or liver transplant: 0.03–0.05 mg/kg/day as a continuous 24-hour IV infusion.
• Adults with heart transplant: 0.01 mg/kg/day as a continuous IV infusion.
• Adults with lung transplant: 0.01–0.03 mg/kg/day as a continuous IV infusion.
• Pediatric liver (and other solid-organ) transplant patients unable to take oral tacrolimus: generally 0.03–0.05 mg/kg/day as continuous IV infusion, adjusted by specialists.

How it is given: Tacrolimus IV is diluted in compatible fluids and infused continuously through a central or carefully monitored peripheral line in the hospital. It is reserved for patients who cannot take oral tacrolimus and is usually continued only for a short period until swallowing or gastrointestinal function allows conversion to capsules or granules; the first oral dose is typically given 8–12 hours after stopping the infusion.

Dose adjustments and special instructions: Doses are individualized based on the transplanted organ, time since transplant, concomitant drugs, kidney and liver function, and tacrolimus blood levels. In patients with impaired kidney or liver function, clinicians start at the lower end of the dosing range and adjust cautiously. Tacrolimus must not be given at the same time as cyclosporine; one should be stopped and adequate time allowed before starting the other.

Missed or interrupted infusions: If an infusion is interrupted or a dose is missed, the transplant team will determine when and how to resume; patients should not adjust infusion rates or restart pumps on their own.

Overdose: Overdose may cause severe kidney injury, dangerous blood pressure or heart rhythm changes, seizures, and profound immunosuppression. Suspected overdose is an emergency; infusion should be stopped and immediate medical evaluation sought, with supportive care and drug-level monitoring provided in hospital.

Common side effects: Frequently reported effects include tremor, headache, trouble sleeping, nausea, diarrhea, loss of appetite, high blood pressure, high blood sugar, and elevated potassium. These often begin soon after starting therapy or after dose increases and may improve as the dose is adjusted or the body adapts.

Serious or rare adverse effects: Tacrolimus can cause kidney damage (rising creatinine, reduced urine output), serious infections (fever, chills, cough, sores that do not heal), severe neurotoxicity (confusion, seizures, vision changes, posterior reversible encephalopathy), heart rhythm problems, new or worsening diabetes, and electrolyte disturbances. Long-term use of potent immunosuppression increases the risk of certain cancers, especially lymphoma and skin cancers; sudden chest pain, shortness of breath, severe headache, or seizures require emergency care.

IV-specific risks: The injection contains a castor-oil derivative and has been associated with anaphylactic reactions in rare cases, so the first part of the infusion is given under close observation with emergency medications and oxygen immediately available.

Warnings and precautions: Use requires great caution in patients with pre-existing kidney or liver impairment, uncontrolled infections, severe heart disease, or a history of serious neurologic events. In pregnancy, tacrolimus is often continued in transplant recipients when benefits outweigh risks; it has been associated with preterm birth and low birth weight, so careful monitoring is required. The drug passes into breast milk; decisions about breastfeeding are individualized between the patient and transplant team. Older adults may be more sensitive to kidney and neurologic effects and typically need closer monitoring and lower target levels.

Comparative safety: Versus cyclosporine, tacrolimus generally causes less cosmetic toxicity (less hirsutism and gum overgrowth) and fewer acute rejection episodes but may cause more neurotoxicity and post-transplant diabetes; both drugs share risks of kidney injury, infections, and malignancy.

Reporting and safety updates: Patients should promptly tell their transplant team about any new or worsening symptoms. In the United States, side effects can also be reported to FDA MedWatch (online or by calling 1-800-FDA-1088), and safety updates are posted on the FDA’s drug safety communications pages.

Major drug and food interactions:

• Drugs that increase tacrolimus levels (raising toxicity risk) include many azole antifungals (for example, ketoconazole, fluconazole, voriconazole), macrolide antibiotics (for example, erythromycin, clarithromycin), certain calcium-channel blockers (for example, diltiazem, verapamil), protease inhibitors, and some antidepressants.
• Drugs that decrease tacrolimus levels (raising rejection risk) include rifampin, carbamazepine, phenytoin, phenobarbital, and the herbal product St. John’s wort.
• Concomitant use with other nephrotoxic agents such as aminoglycoside antibiotics, amphotericin B, high-dose NSAIDs, or frequent iodinated contrast can markedly increase kidney injury risk.
• Grapefruit and grapefruit juice inhibit tacrolimus metabolism and can markedly raise blood levels; they should be avoided.
• Live vaccines should generally be avoided during tacrolimus therapy; responses to inactivated vaccines may be reduced.

Precautions and conditions requiring caution: Tacrolimus IV is contraindicated in patients with known hypersensitivity to tacrolimus or to the polyoxyl 60 hydrogenated castor oil in the injection. Extra caution and close monitoring are needed in patients with kidney or liver disease, uncontrolled hypertension, heart rhythm disorders or prolonged QT interval, diabetes or high diabetes risk, and a history of seizures or severe neurologic disease.

Monitoring requirements: Regular blood tests are essential, including tacrolimus concentrations, kidney and liver function, electrolytes (especially potassium and magnesium), fasting glucose or hemoglobin A1c, and cholesterol. Blood pressure, body weight, and signs of infection or neurologic changes are checked frequently. In higher-risk patients, ECGs may be used to monitor for QT prolongation or other arrhythmias.

Q: Why am I getting tacrolimus by IV instead of by mouth?
A: Intravenous tacrolimus is used when you cannot safely take or absorb the oral form, such as immediately after surgery when you are not eating well; once you can take medicines by mouth reliably, your team will switch you to oral tacrolimus.

Q: How long will I need to stay on tacrolimus after my transplant?
A: The IV form is usually used only for a short time in the hospital, but some form of tacrolimus (usually oral) is often needed long term, sometimes lifelong, to help prevent rejection of your transplanted organ.

Q: Can I eat normally while receiving tacrolimus IV?
A: There are usually no strict food timing rules with IV tacrolimus, but you should avoid grapefruit and grapefruit juice and follow any nutrition instructions from your transplant team.

Q: What symptoms should make me call my transplant team right away?
A: Contact your team urgently if you develop fever or chills, shortness of breath, severe headache, confusion, vision changes, new seizures, chest pain, a sudden drop in urine output, or painful skin lesions or sores that do not heal.

Q: Will tacrolimus IV affect my other medicines?
A: Many drugs can raise or lower tacrolimus levels or increase its side effects, so always tell your transplant team and pharmacist about every prescription, over-the-counter medicine, vitamin, or herbal product you use so they can check for interactions and adjust doses safely.

Storage: Tacrolimus IV is usually stored and prepared by hospital or clinic staff; vials are kept at controlled room temperature, protected from light, and diluted just before use according to professional instructions.

Patient handling: Patients and caregivers at home generally do not store or prepare tacrolimus infusions; if you are sent home with an infusion pump, keep the medicine out of children’s reach, avoid extreme heat or cold, and follow the transplant team’s written directions.

Disposal: Any leftover vials, infusion bags, or tubing should be returned to the clinic or disposed of as medical waste; do not throw tacrolimus solutions in household trash or sinks unless your healthcare team or pharmacy specifically instructs you to do so.